Cognition Therapeutics Publishes Zervimesine Study Results
Cognition Therapeutics announced that a manuscript entitled, "Phase 2 Study of Zervimesine in Participants with Mild-to-Moderate Dementia with Lewy Bodies" has been published in the journal, Alzheimer's & Dementia, the journal of the Alzheimer's Association. Results from this study were first presented in January 2025 at the International Lewy Body Dementia Conference in Amsterdam. "The Phase 2 SHIMMER study, our first in DLB, met its primary goal of confirming zervimesine's safety and tolerability," explained Anthony Caggiano, Cognition's chief medical officer. "Importantly, zervimesine was also shown to have a favorable impact on behavioral, cognitive, functional, and movement domains, many of which are core clinical features of DLB. There are currently no approved disease-modifying treatments for DLB, highlighting the unmet need for novel therapies."
Trade with 70% Backtested Accuracy
Analyst Views on CGTX
About CGTX
About the author
Cognition Advances Zervimesine Development for DLB Psychosis Treatment
- FDA Meeting Outcome: Following the FDA meeting on January 21, 2026, Cognition Therapeutics has decided to pursue a registrational path for zervimesine to treat dementia with Lewy bodies (DLB) psychosis, which affects up to 75% of patients, potentially improving their quality of life and addressing a significant market gap.
- SHIMMER Study Results: In the SHIMMER study, 130 adults with mild-to-moderate DLB received zervimesine, resulting in an 86% improvement in neuropsychiatric symptoms, indicating the drug's potential to enhance daily functioning and possibly transform the treatment landscape for DLB.
- Clinical Trial Design: The next phase of the study will randomize participants to receive either 100mg of zervimesine or a placebo, focusing on measuring symptoms like hallucinations and delusions, which is expected to provide robust data for FDA discussions and expedite the drug's market entry.
- Market Demand: With no approved medications for DLB psychosis and traditional antipsychotics potentially worsening motor function, the development of zervimesine not only meets a critical need but also presents a significant market opportunity for Cognition.
Cognition Extends Expanded Access Program for DLB
- Extended Access Program Duration: Cognition Therapeutics has announced an extension of the treatment duration for its Expanded Access Program (EAP) for dementia with Lewy bodies (DLB) from the original twelve months to several additional months, aimed at gathering more long-term safety data to enhance the reliability of clinical research.
- Positive Patient Feedback: Since its launch in June 2025, the program has enrolled 32 participants, who have provided favorable feedback regarding their treatment experience, indicating strong recognition from patients and their caregivers, which may facilitate future patient recruitment.
- Local Physician Involvement: By empowering local physicians to conduct routine health monitoring and allowing local laboratory testing, Cognition has effectively reduced travel burdens for patients, a strategy that not only enhances patient convenience but may also improve adherence and satisfaction levels among participants.
- FDA Meeting Progress: Cognition held a meeting with the FDA on January 21, 2026, to discuss findings from the SHIMMER study and clinically meaningful endpoints for future research, with meeting minutes expected in February, which will provide crucial guidance for subsequent studies.
Post-Market Winners: A Calm Trading Day Highlighted by a Notable Biotech Rise
DBV Technologies Surge: DBV Technologies S.A. experienced a dramatic 61.29% increase in after-hours trading after announcing successful results from its Phase 3 study of the VIASKIN Peanut patch for peanut-allergic children, reigniting investor interest.
Modular Medical Offering: Modular Medical, Inc. saw a modest gain of 3.53% amid ongoing investor analysis of its recent public offering announcement, which includes over 12 million shares priced at an effective cost of $0.38 per share.
Other Small Gains: Several other companies, including Co-Diagnostics, Elutia Inc., and Treace Medical Concepts, posted small increases in after-hours trading, attributed to light-volume activity rather than specific news.
Amylyx Pharmaceuticals Update: Amylyx Pharmaceuticals advanced 4.83% following its recent presentation of early Phase 1 trial data for AMX0114, which showed promising safety and tolerability, with further enrollment expected soon.
Biotech and Healthcare Stocks Top After-Hours Gainers: ICU, CGTX, MESO, VRCA, AHCO
Biotech Gains in After-Hours Trading: Several small- and mid-cap biotech and healthcare companies saw significant gains in after-hours trading, driven by corporate updates and financing developments.
SeaStar Medical's Leadership Change: SeaStar Medical's stock rose nearly 10% after the appointment of Michael Messinger as Chief Financial Officer, boosting investor confidence despite no new news.
Cognition Therapeutics' Speculative Buying: Cognition Therapeutics rebounded almost 11% in after-hours trading, likely due to speculative buying interest, following a decline during regular trading hours.
Mesoblast's Revenue Projection: Mesoblast's shares increased after management projected over $30 million in gross revenue for the December quarter, indicating strong demand for its cell therapy product, Ryoncil.
HC Wainwright & Co. Affirms Buy Rating for Cognition Therapeutics, Keeps $3 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.
Cognition Therapeutics Finishes Participant Enrollment for Phase 2 Trial of Zervimesine (CT1812) in Early Alzheimer's Disease
Cognition Therapeutics' START Study Enrollment: Cognition Therapeutics has successfully enrolled 540 participants in its Phase 2 START Study, which evaluates the safety and efficacy of zervimesine (CT1812) for treating mild cognitive impairment and early Alzheimer's disease, with results expected after 18 months of treatment.
Collaboration and Support: The study is supported by an $81 million grant from the National Institute of Aging and conducted in partnership with the Alzheimer's Clinical Trials Consortium, highlighting the collaborative effort in Alzheimer's research.
Zervimesine's Unique Mechanism: Zervimesine is an investigational oral drug that targets neurodegenerative diseases by potentially interrupting the toxic effects of harmful proteins in the brain, offering a new treatment avenue for patients who do not respond to existing therapies.
Future Implications for Alzheimer's Treatment: The study aims to explore zervimesine's role in combination therapy for patients already receiving approved monoclonal antibody treatments, potentially expanding treatment options for a broader range of Alzheimer's patients.
Cognition Advances Zervimesine Development for DLB Psychosis Treatment
- FDA Meeting Outcome: Following the FDA meeting on January 21, 2026, Cognition Therapeutics has decided to pursue a registrational path for zervimesine to treat dementia with Lewy bodies (DLB) psychosis, which affects up to 75% of patients, potentially improving their quality of life and addressing a significant market gap.
- SHIMMER Study Results: In the SHIMMER study, 130 adults with mild-to-moderate DLB received zervimesine, resulting in an 86% improvement in neuropsychiatric symptoms, indicating the drug's potential to enhance daily functioning and possibly transform the treatment landscape for DLB.
- Clinical Trial Design: The next phase of the study will randomize participants to receive either 100mg of zervimesine or a placebo, focusing on measuring symptoms like hallucinations and delusions, which is expected to provide robust data for FDA discussions and expedite the drug's market entry.
- Market Demand: With no approved medications for DLB psychosis and traditional antipsychotics potentially worsening motor function, the development of zervimesine not only meets a critical need but also presents a significant market opportunity for Cognition.
Cognition Extends Expanded Access Program for DLB
- Extended Access Program Duration: Cognition Therapeutics has announced an extension of the treatment duration for its Expanded Access Program (EAP) for dementia with Lewy bodies (DLB) from the original twelve months to several additional months, aimed at gathering more long-term safety data to enhance the reliability of clinical research.
- Positive Patient Feedback: Since its launch in June 2025, the program has enrolled 32 participants, who have provided favorable feedback regarding their treatment experience, indicating strong recognition from patients and their caregivers, which may facilitate future patient recruitment.
- Local Physician Involvement: By empowering local physicians to conduct routine health monitoring and allowing local laboratory testing, Cognition has effectively reduced travel burdens for patients, a strategy that not only enhances patient convenience but may also improve adherence and satisfaction levels among participants.
- FDA Meeting Progress: Cognition held a meeting with the FDA on January 21, 2026, to discuss findings from the SHIMMER study and clinically meaningful endpoints for future research, with meeting minutes expected in February, which will provide crucial guidance for subsequent studies.
Post-Market Winners: A Calm Trading Day Highlighted by a Notable Biotech Rise
DBV Technologies Surge: DBV Technologies S.A. experienced a dramatic 61.29% increase in after-hours trading after announcing successful results from its Phase 3 study of the VIASKIN Peanut patch for peanut-allergic children, reigniting investor interest.
Modular Medical Offering: Modular Medical, Inc. saw a modest gain of 3.53% amid ongoing investor analysis of its recent public offering announcement, which includes over 12 million shares priced at an effective cost of $0.38 per share.
Other Small Gains: Several other companies, including Co-Diagnostics, Elutia Inc., and Treace Medical Concepts, posted small increases in after-hours trading, attributed to light-volume activity rather than specific news.
Amylyx Pharmaceuticals Update: Amylyx Pharmaceuticals advanced 4.83% following its recent presentation of early Phase 1 trial data for AMX0114, which showed promising safety and tolerability, with further enrollment expected soon.
Biotech and Healthcare Stocks Top After-Hours Gainers: ICU, CGTX, MESO, VRCA, AHCO
Biotech Gains in After-Hours Trading: Several small- and mid-cap biotech and healthcare companies saw significant gains in after-hours trading, driven by corporate updates and financing developments.
SeaStar Medical's Leadership Change: SeaStar Medical's stock rose nearly 10% after the appointment of Michael Messinger as Chief Financial Officer, boosting investor confidence despite no new news.
Cognition Therapeutics' Speculative Buying: Cognition Therapeutics rebounded almost 11% in after-hours trading, likely due to speculative buying interest, following a decline during regular trading hours.
Mesoblast's Revenue Projection: Mesoblast's shares increased after management projected over $30 million in gross revenue for the December quarter, indicating strong demand for its cell therapy product, Ryoncil.
HC Wainwright & Co. Affirms Buy Rating for Cognition Therapeutics, Keeps $3 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.
Cognition Therapeutics Finishes Participant Enrollment for Phase 2 Trial of Zervimesine (CT1812) in Early Alzheimer's Disease
Cognition Therapeutics' START Study Enrollment: Cognition Therapeutics has successfully enrolled 540 participants in its Phase 2 START Study, which evaluates the safety and efficacy of zervimesine (CT1812) for treating mild cognitive impairment and early Alzheimer's disease, with results expected after 18 months of treatment.
Collaboration and Support: The study is supported by an $81 million grant from the National Institute of Aging and conducted in partnership with the Alzheimer's Clinical Trials Consortium, highlighting the collaborative effort in Alzheimer's research.
Zervimesine's Unique Mechanism: Zervimesine is an investigational oral drug that targets neurodegenerative diseases by potentially interrupting the toxic effects of harmful proteins in the brain, offering a new treatment avenue for patients who do not respond to existing therapies.
Future Implications for Alzheimer's Treatment: The study aims to explore zervimesine's role in combination therapy for patients already receiving approved monoclonal antibody treatments, potentially expanding treatment options for a broader range of Alzheimer's patients.
